The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Further strengthens BaseLaunch's global pharma industry partnerships
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Subscribe To Our Newsletter & Stay Updated
